Insulet Corporation Logo

Insulet Corporation

PODD

(2.0)
Stock Price

267,77 USD

14.47% ROA

46.26% ROE

40.65x PER

Market Cap.

16.079.587.615,00 USD

140% DER

0% Yield

23.22% NPM

Insulet Corporation Stock Analysis

Insulet Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Insulet Corporation Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (22.42%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 Revenue Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

3 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

4 ROA

The stock's ROA (5.18%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

5 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (25.643) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

6 PBV

The stock's elevated P/BV ratio (20.01x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

7 DER

The company has a high debt to equity ratio (234%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

8 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

9 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

10 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

11 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

Insulet Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Insulet Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Insulet Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Insulet Corporation Revenue
Year Revenue Growth
2002 0
2003 0 0%
2004 0 0%
2005 50.000 100%
2006 3.663.000 98.63%
2007 13.372.000 72.61%
2008 36.059.000 62.92%
2009 66.032.000 45.39%
2010 96.966.000 31.9%
2011 152.255.000 36.31%
2012 211.369.000 27.97%
2013 247.084.000 14.45%
2014 288.720.000 14.42%
2015 263.893.000 -9.41%
2016 366.989.000 28.09%
2017 463.768.000 20.87%
2018 563.823.000 17.75%
2019 738.200.000 23.62%
2020 904.400.000 18.38%
2021 1.098.800.000 17.69%
2022 1.305.300.000 15.82%
2023 1.730.800.000 24.58%
2023 1.697.100.000 -1.99%
2024 1.954.000.000 13.15%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Insulet Corporation Research and Development Expenses
Year Research and Development Expenses Growth
2002 9.458.000
2003 8.659.000 -9.23%
2004 9.026.000 4.07%
2005 10.764.000 16.15%
2006 8.094.000 -32.99%
2007 10.391.000 22.11%
2008 13.104.000 20.7%
2009 13.231.000 0.96%
2010 16.566.000 20.13%
2011 21.863.000 24.23%
2012 24.359.000 10.25%
2013 21.765.000 -11.92%
2014 27.900.000 21.99%
2015 43.208.000 35.43%
2016 55.710.000 22.44%
2017 74.452.000 25.17%
2018 88.606.000 15.97%
2019 129.700.000 31.68%
2020 146.800.000 11.65%
2021 160.100.000 8.31%
2022 180.200.000 11.15%
2023 231.200.000 22.06%
2023 205.000.000 -12.78%
2024 215.600.000 4.92%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Insulet Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
2002 0
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 30.063.000 100%
2008 63.484.000 52.64%
2009 26.842.000 -136.51%
2010 26.667.000 -0.66%
2011 44.083.000 39.51%
2012 51.240.000 13.97%
2013 64.077.000 20.03%
2014 66.841.000 4.14%
2015 60.392.000 -10.68%
2016 71.597.000 15.65%
2017 88.487.000 19.09%
2018 111.818.000 20.87%
2019 115.500.000 3.19%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Insulet Corporation EBITDA
Year EBITDA Growth
2002 -12.672.000
2003 -12.014.000 -5.48%
2004 -13.497.000 10.99%
2005 -20.269.000 33.41%
2006 -32.005.000 36.67%
2007 -48.922.000 34.58%
2008 -81.172.000 39.73%
2009 -53.896.000 -50.61%
2010 -33.388.000 -61.42%
2011 -35.825.000 6.8%
2012 -24.831.000 -44.28%
2013 -16.179.000 -53.48%
2014 -24.448.000 33.82%
2015 -36.278.000 32.61%
2016 1.270.000 2956.54%
2017 6.500.000 80.46%
2018 49.774.000 86.94%
2019 77.000.000 35.36%
2020 110.300.000 30.19%
2021 139.600.000 20.99%
2022 109.500.000 -27.49%
2023 222.000.000 50.68%
2023 323.600.000 31.4%
2024 295.200.000 -9.62%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Insulet Corporation Gross Profit
Year Gross Profit Growth
2002 0
2003 0 0%
2004 0 0%
2005 -1.480.000 100%
2006 -11.997.000 87.66%
2007 -12.361.000 2.94%
2008 -4.584.000 -169.66%
2009 18.297.000 125.05%
2010 43.726.000 58.16%
2011 66.712.000 34.46%
2012 92.336.000 27.75%
2013 112.401.000 17.85%
2014 143.288.000 21.56%
2015 133.271.000 -7.52%
2016 211.086.000 36.86%
2017 277.169.000 23.84%
2018 370.168.000 25.12%
2019 480.300.000 22.93%
2020 582.300.000 17.52%
2021 752.100.000 22.58%
2022 805.600.000 6.64%
2023 1.173.200.000 31.33%
2023 1.159.900.000 -1.15%
2024 1.336.800.000 13.23%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Insulet Corporation Net Profit
Year Net Profit Growth
2002 -12.580.000
2003 -11.941.000 -5.35%
2004 -13.821.000 13.6%
2005 -21.636.000 36.12%
2006 -35.950.000 39.82%
2007 -53.539.000 32.85%
2008 -92.791.000 42.3%
2009 -79.541.000 -16.66%
2010 -61.159.000 -30.06%
2011 -57.170.000 -6.98%
2012 -51.867.000 -10.22%
2013 -44.974.000 -15.33%
2014 -51.500.000 12.67%
2015 -73.520.000 29.95%
2016 -28.879.000 -154.58%
2017 -26.831.000 -7.63%
2018 3.292.000 915.04%
2019 11.600.000 71.62%
2020 6.800.000 -70.59%
2021 16.800.000 59.52%
2022 4.600.000 -265.22%
2023 207.600.000 97.78%
2023 206.300.000 -0.63%
2024 754.400.000 72.65%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Insulet Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2002 -42
2003 -44 2.33%
2004 -48 8.51%
2005 -71 32.86%
2006 -99 29.29%
2007 -3 -3200%
2008 -3 0%
2009 -3 -50%
2010 -2 -100%
2011 -1 0%
2012 -1 0%
2013 -1 0%
2014 -1 0%
2015 -1 100%
2016 -1 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 3 100%
2023 3 0%
2024 11 80%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Insulet Corporation Free Cashflow
Year Free Cashflow Growth
2004 -15.764.000
2005 -25.793.000 38.88%
2006 -44.957.000 42.63%
2007 -60.461.000 25.64%
2008 -92.658.000 34.75%
2009 -52.463.000 -76.62%
2010 -42.174.000 -24.4%
2011 -36.566.000 -15.34%
2012 -40.050.000 8.7%
2013 -3.959.000 -911.62%
2014 -2.566.000 -54.29%
2015 -23.160.000 88.92%
2016 -6.204.000 -273.31%
2017 -36.019.000 82.78%
2018 -126.455.000 71.52%
2019 -72.500.000 -74.42%
2020 -82.500.000 12.12%
2021 -190.800.000 56.76%
2022 -38.300.000 -398.17%
2023 36.200.000 205.8%
2023 35.900.000 -0.84%
2024 71.600.000 49.86%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Insulet Corporation Operating Cashflow
Year Operating Cashflow Growth
2004 -13.056.000
2005 -20.321.000 35.75%
2006 -31.820.000 36.14%
2007 -50.372.000 36.83%
2008 -82.611.000 39.03%
2009 -49.323.000 -67.49%
2010 -35.625.000 -38.45%
2011 -25.452.000 -39.97%
2012 -29.059.000 12.41%
2013 3.348.000 967.95%
2014 8.920.000 62.47%
2015 -12.552.000 171.06%
2016 15.911.000 178.89%
2017 41.207.000 61.39%
2018 35.899.000 -14.79%
2019 98.400.000 63.52%
2020 84.000.000 -17.14%
2021 -68.100.000 223.35%
2022 119.000.000 157.23%
2023 145.400.000 18.16%
2023 56.000.000 -159.64%
2024 96.500.000 41.97%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Insulet Corporation Capital Expenditure
Year Capital Expenditure Growth
2004 2.708.000
2005 5.472.000 50.51%
2006 13.137.000 58.35%
2007 10.089.000 -30.21%
2008 10.047.000 -0.42%
2009 3.140.000 -219.97%
2010 6.549.000 52.05%
2011 11.114.000 41.07%
2012 10.991.000 -1.12%
2013 7.307.000 -50.42%
2014 11.486.000 36.38%
2015 10.608.000 -8.28%
2016 22.115.000 52.03%
2017 77.226.000 71.36%
2018 162.354.000 52.43%
2019 170.900.000 5%
2020 166.500.000 -2.64%
2021 122.700.000 -35.7%
2022 157.300.000 22%
2023 109.200.000 -44.05%
2023 20.100.000 -443.28%
2024 24.900.000 19.28%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Insulet Corporation Equity
Year Equity Growth
2002 -18.653.000
2003 -30.650.000 39.14%
2004 -44.509.000 31.14%
2005 -66.091.000 32.65%
2006 -101.765.000 35.06%
2007 92.275.000 210.28%
2008 4.274.000 -2058.98%
2009 52.857.000 91.91%
2010 66.231.000 20.19%
2011 71.396.000 7.23%
2012 44.176.000 -61.62%
2013 124.597.000 64.54%
2014 83.829.000 -48.63%
2015 34.051.000 -146.19%
2016 63.150.000 46.08%
2017 158.516.000 60.16%
2018 212.099.000 25.26%
2019 75.900.000 -179.45%
2020 603.600.000 87.43%
2021 556.300.000 -8.5%
2022 476.400.000 -16.77%
2023 732.700.000 34.98%
2023 607.500.000 -20.61%
2024 998.400.000 39.15%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Insulet Corporation Assets
Year Assets Growth
2002 17.511.000
2003 4.958.000 -253.19%
2004 27.121.000 81.72%
2005 16.792.000 -61.51%
2006 57.140.000 70.61%
2007 130.741.000 56.3%
2008 109.229.000 -19.69%
2009 171.648.000 36.36%
2010 156.233.000 -9.87%
2011 209.583.000 25.46%
2012 198.059.000 -5.82%
2013 287.955.000 31.22%
2014 302.156.000 4.7%
2015 275.126.000 -9.82%
2016 456.647.000 39.75%
2017 816.744.000 44.09%
2018 928.744.000 12.06%
2019 1.142.900.000 18.74%
2020 1.872.900.000 38.98%
2021 2.048.800.000 8.59%
2022 2.251.100.000 8.99%
2023 2.588.200.000 13.02%
2023 2.467.700.000 -4.88%
2024 2.881.600.000 14.36%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Insulet Corporation Liabilities
Year Liabilities Growth
2002 36.164.000
2003 35.608.000 -1.56%
2004 71.630.000 50.29%
2005 82.883.000 13.58%
2006 158.905.000 47.84%
2007 38.466.000 -313.11%
2008 104.955.000 63.35%
2009 118.791.000 11.65%
2010 90.002.000 -31.99%
2011 138.187.000 34.87%
2012 153.883.000 10.2%
2013 163.358.000 5.8%
2014 218.327.000 25.18%
2015 241.075.000 9.44%
2016 393.497.000 38.74%
2017 658.228.000 40.22%
2018 716.645.000 8.15%
2019 1.067.000.000 32.84%
2020 1.269.300.000 15.94%
2021 1.492.500.000 14.95%
2022 1.774.700.000 15.9%
2023 1.855.500.000 4.35%
2023 1.860.200.000 0.25%
2024 1.883.200.000 1.22%

Insulet Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
26.73
Net Income per Share
5.64
Price to Earning Ratio
40.65x
Price To Sales Ratio
8.59x
POCF Ratio
56.38
PFCF Ratio
88.3
Price to Book Ratio
16.09
EV to Sales
8.95
EV Over EBITDA
71.27
EV to Operating CashFlow
58.81
EV to FreeCashFlow
92.05
Earnings Yield
0.02
FreeCashFlow Yield
0.01
Market Cap
16,08 Bil.
Enterprise Value
16,76 Bil.
Graham Number
42.53
Graham NetNet
-8.35

Income Statement Metrics

Net Income per Share
5.64
Income Quality
0.72
ROE
0.51
Return On Assets
0.14
Return On Capital Employed
0.13
Net Income per EBT
1.42
EBT Per Ebit
0.92
Ebit per Revenue
0.18
Effective Tax Rate
-0.47

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.11
Stock Based Compensation to Revenue
0.03
Gross Profit Margin
0.76
Operating Profit Margin
0.18
Pretax Profit Margin
0.16
Net Profit Margin
0.23

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
4.07
Free CashFlow per Share
2.6
Capex to Operating CashFlow
0.36
Capex to Revenue
0.05
Capex to Depreciation
1.36
Return on Invested Capital
0.19
Return on Tangible Assets
0.14
Days Sales Outstanding
67.94
Days Payables Outstanding
48.83
Days of Inventory on Hand
273.96
Receivables Turnover
5.37
Payables Turnover
7.48
Inventory Turnover
1.33
Capex per Share
1.47

Balance Sheet

Cash per Share
11,72
Book Value per Share
14,25
Tangible Book Value per Share
12.11
Shareholders Equity per Share
14.25
Interest Debt per Share
19.67
Debt to Equity
1.4
Debt to Assets
0.49
Net Debt to EBITDA
2.9
Current Ratio
3.56
Tangible Asset Value
0,85 Bil.
Net Current Asset Value
-0,15 Bil.
Invested Capital
2073200000
Working Capital
1,25 Bil.
Intangibles to Total Assets
0.05
Average Receivables
0,33 Bil.
Average Payables
0,08 Bil.
Average Inventory
430750000
Debt to Market Cap
0.09

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Insulet Corporation Dividends
Year Dividends Growth

Insulet Corporation Profile

About Insulet Corporation

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

CEO
Dr. James R. Hollingshead Ph.D
Employee
3.000
Address
100 Nagog Park
Acton, 01720

Insulet Corporation Executives & BODs

Insulet Corporation Executives & BODs
# Name Age
1 Mr. Mark Field
Senior Vice President & Chief Technology Officer
70
2 Ms. Ana Maria Chadwick
Executive Vice President, Chief Financial Officer & Treasurer
70
3 Mr. Eric Benjamin
Executive Vice President, Chief Product & Customer Experience Officer
70
4 Ms. Lauren Budden
Group Vice President, Chief Accounting Officer & Controller
70
5 Mr. John Wodick Kapples J.D.
Senior Vice President & General Counsel
70
6 Dr. James R. Hollingshead Ph.D.
President, Chief Executive Officer & Director
70
7 June Lazaroff
Senior Director of Investor Relations
70
8 Mr. Prem Singh
Senior Vice President of Global Operations
70
9 Ms. Laetitia Cousin
Senior Vice President of Regulatory Affairs, Quality Assurance & Compliance
70
10 Angela Geryak Wiczek
Senior Director of Corporate Communications
70

Insulet Corporation Competitors